Lindsey Shapiro, PhD, science writer —

Dipraglurant, an investigational oral therapy from Addex Therapeutics, eased motor and nonmotor symptoms associated with Parkinson’s disease in rodent models, a study showed. Along with being rapidly absorbed in the bloodstream, dipraglurant demonstrated anti-parkinsonian effects and reduced behaviors associated with anxiety, depression, and obsessive-compulsive disorder in mice and…

Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…

Women who undergo surgery to remove both of their ovaries before age 43 have a five times higher risk of developing Parkinson’s disease in the future, according to a U.S. study. For younger women who had the procedure, called a bilateral oophorectomy, use of estrogen replacement therapy until the…

While dopamine-replacing therapies are a key component of Parkinson’s disease care, they only reflect a person’s physical characteristics or the state of their disease. Adding a dose of “hopamine” — a person’s own unique set of hopes, desires, experiences, and skills — to Parkinson’s care takes patients’ personal characteristics…

BlueRock Therapeutics will use digital health technologies from Rune Labs and Emerald Innovations to remotely monitor a subset of Parkinson’s disease patients in an observational clinical study. The goal of the two-year study (NCT05363046) is to shed light on patients’ daily experiences with the neurodegenerative disease via…

The sixth annual Parkinson’s Expo, a free and educational conference covering a range of topics related to Parkinson’s disease, is set for Saturday, March 25, in Palmetto, Florida and virtually. Hosted by the Neuro Challenge Foundation and designed with input from the Parkinson’s community, the event is intended to…

The Parkinson’s Foundation was awarded nearly $800,000 to support research efforts that aim to improve the lives of the estimated 18,000 people living with Parkinson’s disease in Arizona. The focus of the new grant, from the Pat Simone Charitable Foundation, located in Arizona, is to improve genetic testing,…

Parkinson’s disease patients with inadequately controlled tremors are being sought for a Phase 2 clinical trial of suvecaltamide, an oral treatment candidate from Jazz Pharmaceuticals. The Phase 2 trial (NCT05642442), which enrolled its first participant late last year, seeks about 160 adults, ages 40-80, with Parkinson’s who have…

Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild cognitive impairment (MCI) due to Parkinson’s disease. The trial is recruiting Parkinson’s patients at 16 sites across the U.S. Dubbed PRECEDENT (NCT05318937), it’s designed to investigate SAGE-718’s…

Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for Parkinson’s disease. The funding comes in the form of a Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM). Ryne plans to use the award…